Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors

European Heart Journal, Supplement

Volumn 3, Issue SUPPL.9, 2001, Pages 123-130

  Cruz Fernandez J M ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b NONE   (Spain)

Author keywords

Acute coronary syndromes; Antiplatelet agents; Aspirin; Cyclooxygenase inhibitors; Triflusal

Indexed keywords

EID: 10644283063     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Knight CJ. New insights into the pathophysiology of acute coronary occlusion. Eur Heart J Suppl 1999; 1 (Suppl F): F3-F6.
2. Kaski JC. Local cytokine production and acute coronary events. Int J Cardiol 2000; 73: 79-81.
3. Badimón JJ, Lettino M, Toschi V et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effect of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
4. Rupprecht HJ. Adenosine diphosphate receptor antagonists: from pharmacology to clinical practice. Eur Heart J 2000; (Suppl E): E1-5.m
5. Task Force of the European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-32.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of ramdomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
7. Lewis HD, Davis JW, Archibald DJ et al Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administrative Group Study. N Engl J Med 1983; 309: 396-403.
8. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
9. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 1985; 313: 1369-75.
10. Theroux P, Quimet H, McCans J et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349-60.
12. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
13. Al-Khadra AS, Salem DN, Rand WM et al. Antiplatelet agents and survival. A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31: 419-25.
14. Vane JR. Towards a better aspirin. Nature (London) 1994; 367: 215-6.
15. Lipsky PE, Brooks P, Crofford LJ et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160: 913-20.
16. Gutthann SP. Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 2433-9.
17. Vane JR, Botting RM. Mechanisms of action of aspirin-like drugs. Sem Arthritis Rheum 1997; 26: 2-10.
18. Van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors. Pharmacology, clinical effects and therpeutic potential. Exp Opin Invest Drugs 1997; 6: 609-14.
19. Cohn SM, Schloemann S, Tessner T et al. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest. 1997; 99: 1367-79.
20. Langenbach R, Morham SG, Tirano HF et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacine-induced gastric ulceration. Cell 1995; 83: 483-92.
21. McAdam BF, Catella-Lawson F, Mardini NA et al. Systemic biosynthesis of prostacyclin by cyclooxygense (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
22. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 1998; 355: 211-7.
23. Willoughby DA, Moore AR, Colvill-Nash PR. COX-1, COX-2 and COX-3 and the treatment of chronic inflammatory disease. Lancet 2000; 355: 646-8.
24. Hawkay CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
25. Sanchez de Miguel L, Montón M, Arriero MM et al. Effect of triflusal on human platelet aggregation and secretion: role of nitric oxide. Rev Esp Cardiol 2000; 53: 205-11.
26. Carcia-Rafanell J, Ramis J, Gomez L et al. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986; 284: 155-65.
27. Bayón Y, Alonso A, Sanchez Crespo M. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor κB activation. Br J Pharmacol 1999; 126: 1359-66.
28. Laufer S, Striegel HG, Neher C et al. Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors. Arch Pharm (Weinheim) 1997; 330: 307-12.
29. De la Cruz JP, Pavia J, Garcia-Arnés J et al. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur J Haematol 1988; 40: 232-6.
30. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxene in patients with rheumatoid arthritis. N Engl J Med 2000; 346: 1520-8.
31. Cruz-Fernández JM, Lopez V, Marfil F et al. Managing acute myocardial infarction: clinical implications of the TIM study. Eur Heart J Suppl 1999; 1 (Suppl F): F12-8.
32. McNeely W, Goa KL. Triflusal. Drugs 1998; 55: 823-33.
33. Bayés de Luna A. May aspirin be replaced in the treatment of myocardial infarction? Eur Heart J 2000; 21: 430-2.
34. Guiteras P, Altimiras J, Aris A et al. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-bind, placebo-controlled trial. Eur Heart J 1989; 10: 159-67.
35. Masotti M, Tura A, Crexels C et al. Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty. J Int Med Res 1991; 19: 414-8.
36. Plaza L, López-Bescós L, Martin-Jadraque L et al. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicentre trial. Grupo de Estudio del Triflusal en la Angina Inestable. Cardiology 1993; 82: 388-98.
37. Cruz-Fernández JM, López-Bescós L, García-Dorado D et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-65.
38. López Bescós L, Cabades A, Castro-Beiras A et al. Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment. Eur Heart J Suppl 2000; 1 (Suppl F): F19-23.
39. Garcíá-Dorado D, Velasco J, Virgós A et al. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J Suppl 2000; 1 (Suppl F): F24-8.